AsianFin -- Shares of Novo Nordisk dropped nearly 4% on Friday to their lowest level since August 2021, after U.S. President Donald Trump urged major pharmaceutical companies to lower drug prices in the U.S.

The decline capped a brutal week for the maker of Wegovy, with shares plunging over 30%—the worst weekly performance in the company’s history—following a sharp cut to its 2025 sales outlook and the appointment of long-time executive Maziar Mike Doustdar as CEO.